drugset
drugset / Trial / NCT02229760

Effect of Steady State TPV/r on Intracellular Concentrations of Zidovudine and Carbovir for Patients With HIV

NCT02229760 ↗

Phase 1/2 Terminated 3 enrolled Boehringer Ingelheim
Non-randomizedSingle-groupOpen-labelTreatment

Summary

To determine the effect of steady-state tipranavir 500 mg/ritonavir 200 mg (TPV/r) on intracellular concentrations of zidovudine triphosphate (ZDV-TP) and carbovir triphosphate (CBV-TP) and plasma viral load

Timeline

Start
2006-08
Primary completion
2007-09
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Tipranavir Small molecule 500 mg —
Background Ritonavir Other / unclassified 200 mg —

Indications

HIV infectious disease